Disability and Depressiveness are Related to IL-18 Serum Levels in the Remission of Multiple Sclerosis
References
- Sospedra M and Martin M. Immunology of multiple sclerosis. Annals Review Immunology 2005; 23: 683–747.
- Graber JJ, Ford D, Zhan M, Francis G, Panitch H and Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlation with interferon dose and MRI response. J Neuroimmunol 2007; 185: 168–174.
- Musette P, Benveniste O, Lim A, Bequet D, Kowilsky P, Dormont D et al. The pattern of production of cytokine mRNAs is markedly altered at the onset of multiple sclerosis. Res Immunol 1996; 147: 435–441.
- Monteyne P, Van Antwerpen MP, Sindic CJ. Expression of costimulatory molecules and cytokines in CSF and peripheral blood mononuclear cells from multiple sclerosis patients. Acta Neurol Belg 1999; 99: 11–20.
- Trenova AG, Manova MG, Kostadinova II, Hrsitova DR, Vasileva TV and Zahariev ZI: Clinical and laboratory study of pro-inflammatory and anti-inflammatory cytokines in women with multiple sclerosis. Folia Med 2011; 53: 29–35.
- Kallaur AP, Oliveira SR, Colado Simão AN, Delicato de Almeida ER, Kaminami Morimoto H, Lopes J et al. Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease. Molecular Medicine Reports 2013; 7: 1010–1020.
- Bradl M. Immune control of the brain. Springer Semin Immunopathol 1996; 18 (1): 35–49.
- Dantzer R, Heijnen CJ, Kavelaars A, Laye S, Capuron L. The neuroimmune basis of fatigue. Trends Neurosci 2014; 37: 39–46.
- Sha Q, Madaj Z, Keaton S, Escobar Galvis ML, Smart L, Krzyzanowski S et al. Cytokines and tryptophan metabolites can predict depressive symptoms in pregnancy. Transl Psychiatry 2022; 12 (1): 35.
- Clark IA, Budd AC, Alleva LM. Sickness behaviour pushed too far-the basis of the syndrome seen in severe protozoal, bacterial and viral disease and posttrauma. Malar J 2008; 7: 208–215.
- Bluthe RM, Walter V, Parnet P, Layé S, Lestage J, Verrier D et al. Lipopolysacharide induced sickness behaviour in rats by a vagal mediated mechanism. Compt Rend l’Acad Sci III 1994: 317: 499–503.
- Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelly KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46–56.
- Lasselin J. Back to the future of psychoneuroimmunology: Studying inflammation-induced sickness behavior. Brain Behav Immun Health 2021; 18: 100379.
- Pollak Y, Ovadia H, Orion E, Weidenfeld J, Yirmiya R. The EAE-associated behavioral syndrome: I. Temporal correlation with inflammatory mediators. J Neuroimmunol 2003; 137 (1–2): 94–99.
- Pollak Y, Ovadia H, Orion E, Yirmiya R. The EAEassociated behavioral syndrome: II. Modulation by antiinflammatory treatments. J Neuroimmunol 2003; 137 (1–2): 100–108.
- Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. International Journal of Molecular Sciences 2019; 20 (23): 6008.
- Lin CC, Edelson BT. New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. J Immunol 2017; 198 (12): 4553–4560.
- Bai Z, Chen D, Wang L, Zhao Y, Liu T, Yu Y et al. . Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: A Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients. Front Neurosci 2019; 13: 1026.
- Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018; 57 (11): 1885–1895.
- Bårdsen K, Brede C, Kvivik I, Kvaløy JT, Jonsdottir K, Tjensvoll AB et al. Interleukin-1-related activity and hypocretin-1 in cerebrospinal fluid contribute to fatigue in primary Sjögren's syndrome. J Neuroinflammation. 2019; 16 (1): 102.
- Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol 2014; 10: 507–517.
- Tarasiuk J, Kapica-Topczewska K, Czarnowska A, Chorąży M, Kochanowicz J, Kułakowska A. Co-occurrence of Fatigue and Depression in People With Multiple Sclerosis: A Mini-Review. Front Neurol 2022; 12: 817256.
- Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun 2020; 87: 901–909.
- Solaro C, Bergamaschi R, Rezzani C, Mueller M, Trabucco E, Bargiggia V, et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study Clin Neuropharmacol 2013; 36: 114–116.
- Govindarajan V, de Rivero Vaccari JP, Keane RW. Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets. J Neuroinflammation 2020; 17: 260.
- Ihim SA, Abubakar SD, Zian Z, Sasaki T, Saffarioun M, Maleknia S et al. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment. Front Immunol 2022; 13: 919973.
- Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223: 20–38.
- Akita K, Ohtsuki T, Nukada Y, Tanimoto T, Namba M, Okura T et al. Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells. J Biol Chem 1997; 272: 26595–26603.
- Fukaura H, Kikuchi S. [IL-18 in multiple sclerosis]. Nihon Rinsho. Japanese Journal of Clinical Medicine 2003; 61(8): 1416–1421.
- Olcum M., Tastan B., Kiser C., Genc S., Genc K. Microglial NLRP3 inflammasome activation in multiple sclerosis. Advances in Protein Chemistry and Structural Biology 2020; 119: 247–308.
- Miyoshi K, Obata K, Kondo T, Okamura H, Noguchi K: Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury. J Neurosci 2008; 28: 12775–12787.
- Kanai T, Kamada N, Hisamatsu T. Clinical strategies for the blockade of IL-18 in inflammatory bowel diseases. Curr Drug Targets 2013; 14: 1392–1399.
- Shao XT, Feng L, Gu LJ, Wu LJ, Feng TT, Yang YM, et al. Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis. Clin Exp Med 2009; 9: 215–221.
- Shimizu M, Nakagishi Y, Yoshida A, Yachie A. Serum interleukin 18 as a diagnostic remission criterion in systemic juvenile idiopathic arthritis. J Rheumatol 2014; 41: 2328–2330.
- Wu CY, Yang HY, Yao TC, Liu SH, Huang JL. Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients. Medicine (Baltimore) 2016; 95: e5037.
- Satış H, Özger HS, Aysert Yıldız P, Hızel K, Gulbahar Ö, Erbaş G et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine 2021; 137: 155302.
- Spitsin S, Koprowski H. Role of uric acid in multiple sclerosis. Curr Top Microbiol Immunol 2008; 318: 325–342.
- Piancone F, Saresella M, Marventano I, La Rosa F, Santangelo MA, Caputo D et al. Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. Front Immunol 2018; 9: 983.
- Katarina V, Gordana T, Svetlana MD, Milica B. Oxidative stress and neuroinflammation should be both considered in the occurrence of fatigue and depression in multiple sclerosis. Acta Neurol Belg 2020; 120(4): 853–861.
- Dantzer R, Kelley KW: Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007; 21: 153–160.
- Jahanbani-Ardakani H, Alsahebfosoul F, Etemadifar M, Abtahi SH. Interleukin 18 Polymorphisms and its serum level in Patients with Multiple Sclerosis. Ann Indian Acad Neurol 2019; 22 (4): 474–476.
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69 (2): 292–302.
- Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61 (11): 1528–1532.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33 (11): 1444–1452.
- Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB et al. Guideline Development Subcommittee of the American Academy of Neurology. Evidencebased guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82 (2): 174–181.
- Krupp LB, La Rocca NG, Muir-Nash J, Steinbery AD. The fatigue severity scales. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46 (10): 1121–1123.
- Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423–474.
- Jander S, Stoll G. Differential induction of interleukin-12, interleukin-18, and interleukin-1beta converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat. J Neuroimmunol 1998; 91 (1–2): 93–99.
- Gutcher I, Urich E, Wolter K, Prinz M, Becher B. Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol 2006; 7 (9): 946–953.
- Karakas Celik S, Öz ZS, Dursun A, Unal A, Emre U, Cicek S et al. Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis. Mol Biol Rep 2014; 41: 1653–1658.
- Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci 1999; 96(12): 6873–6878.
- Wildbaum G, Youssef S, Grabie N, Karin N. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J Immunol 1998; 161 (11): 6368–6374.
- Chen YC, Chen SD, Miao L, Liu ZG, Li W, Zhao ZX et al. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol 2012; 243 (1–2): 56–60.
- Nicoletti F, Di Marco R, Mangano K, Patti F, Reggio E, Nicoletti A et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 2001; 57 (2): 342–344.
- Huang WX, Huang P, Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Multiple Sclerosis Journal 2004; 10 (5): 482–487.
- Losy J. and Niezgoda A. IL-18 in patients with multiple sclerosis. Acta Neurologica Scandinavica 2001; 104: 171–173.
- Trenova AG, Slavov GS, Draganova-Filipova MN, Mateva NG, Manova MG, Miteva LD et al. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. Neurol Res 2018; 40 (3): 153–159.
- Yang JW, Mao B, Tao RJ, Fan LC, Lu HW, Ge BX, Xu JF. Corticosteroids alleviate lipopolysaccharide-induced inflammation and lung injury via inhibiting NLRP3-inflammasome activation. J Cell Mol Med. 2020; 24(21): 12716–12725.
- Wu L, Zhou C, Wu J, Chen S, Tian Z, Du Q. Corticosterone Inhibits LPS-Induced NLRP3 Inflammasome Priming in Macrophages by Suppressing Xanthine Oxidase. Mediators Inflamm. 2020; 2020: 6959741.
- Soares JL, Oliveira EM, Pontillo A. Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis. Mult Scler Relat Disord. 2019; 29: 26–34.
- Yamanishi K, Doe N, Mukai K, Ikubo K, Hashimoto T, Uwa N et al. Interleukin-18-deficient mice develop hippocampal abnormalities related to possible depressivelike behaviors. Neuroscience 2019; 408: 147–160.
- Yamanishi K, Doe N, Mukai K, Hashimoto T, Gamachi N, Hata M et al. Acute stress induces severe neural inflammation and overactivation of glucocorticoid signaling in interleukin-18-deficient mice. Transl Psychiatry 2022; 12 (1): 404.
- Wu D, Zhang G, Zhao C, Yang Y, Miao Z, Xu X. Interleukin-18 from neurons and microglia mediates depressive behaviors in mice with post-stroke depression. Brain Behav Immun 2020; 88: 411–420.
- Haastrup E, Bukh JD, Bock C, Vinberg M, Thørner LW, Hansen T et al. Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. J Affect Disord 2012; 136 (1–2): 134–138.
- Merendino RA, Di Rosa AE, Di Pasquale G, Minciullo PL, Mangraviti C, Costantino A et al. Interleukin-18 and CD30 serum levels in patients with moderate-severe depression. Mediators Inflamm 2002; 11 (4): 265–267.
- Alcocer-Gomez E, de Miguel M, Casas-Barquero N, Nunez-Vasco J, Sanchez-Alcazar JA, Fernandez-Rodriguez A et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun 2014; 36: 111–117.
- Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFalpha proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord 2015; 182: 106–114.
- Du X, Zou S, Yue Y, Fang X, Wu Y, Wu S et al. Peripheral Interleukin-18 is negatively correlated with abnormal brain activity in patients with depression: a resting-state fMRI study. BMC Psychiatry 2022; 22 (1): 531.
- Zhao N, Dong C. Correlation of Serum IL-18, BDNF, and IL-1β with Depression and Prognosis after Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Comput Math Methods Med. 2022; 2022:3555982. Retraction in: Comput Math Methods Med 2022; 2022:9893716.
- Wedervang-Resell K, Friis S, Lonning V, Smelror RE, Johannessen C, Reponen EJ et al. Increased interleukin 18 activity in adolescents with early-onset psychosis is associated with cortisol and depressive symptoms. Psychoneuroendocrinology 2020; 112: 104513.
- Liu CH, Zhang GZ, Li B, Li M, Woelfer M, Walter M, Wang L. Role of inflammation in depression relapse. J Neuroinflammation 2019; 16(1): 90.
- Herman FJ, Pasinetti GM. Principles of inflammasome priming and inhibition: Implications for psychiatric disorders. Brain Behav Immun 2018; 73:66–84
- Al-Hakeim HK, Twayej AJ, Al- Dujaili AH. Reduction in serum IL-1β, IL-6, and IL-18 levels and Beck Depression Inventory-II score by combined sertraline and ketoprofen administration in major depressive disorder: A clinical trial. Neurol Psychiatry Brain Res 2018; 30: 148–153.
DOI: https://doi.org/10.2478/eabr-2024-0002 | Journal eISSN: 2956-2090 (formerly 2335-075X, 2956-0454) | Journal ISSN: 2956-0454 (formerly 1820-8665)
Language: English
Page range: 149 - 158
Submitted on: Oct 25, 2023
Accepted on: Feb 8, 2024
Published on: Oct 24, 2026
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Related subjects:
© 2026 Katarina Vesic, Aleksandar Arsenijevic, Jelena Milovanovic, Nataša R. Mijailović, Aleksandar Gavrilovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.